William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia (CLL).

The combination of ibrutinib (Imbruvica), cyclophosphamide, fludarabine, and obinutuzumab (Gazyva) is currently being tested at MD Anderson in younger patients with a mutated immunoglobulin heavy chain variable gene.

Additionally, a study of ibrutinib plus venetoclax (Venclexta) is currently ongoing, and data on that combination will be presented at this year’s ASH Annual Meeting.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

NCCN Hematologic Malignancies Congress

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia. 

Dr. Wierda Discusses Trials of Novel Combinations in CLL